| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0920-9964(98)00159-5 |
| P8608 | Fatcat ID | release_43z2ysoztbhtvpivmv5bsu452i |
| P698 | PubMed publication ID | 10190228 |
| P2093 | author name string | R A Dickson | |
| W M Glazer | |||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | S75-86 | |
| P577 | publication date | 1999-03-01 | |
| P1433 | published in | Schizophrenia Research | Q7431607 |
| P1476 | title | Neuroleptic-induced hyperprolactinemia | |
| P478 | volume | 35 Suppl |
| Q94554721 | A 30-year-old woman with galactorrhea |
| Q36322256 | A risperidone-induced prolactinoma resolved when a woman with schizoaffective disorder switched to ziprasidone: a case report |
| Q38206238 | A systematic review of instruments to measure sexual functioning in patients using antipsychotics. |
| Q34230366 | Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities |
| Q46886132 | Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study |
| Q44428863 | Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials |
| Q51292022 | Attitudes toward menstruation in females with schizophrenia or schizoaffective disorders in Taiwan. |
| Q35102472 | Detection and management of comorbidity in patients with schizophrenia |
| Q35688765 | Dopamine partial agonists: a new class of antipsychotic |
| Q35820327 | Dose response and atypical antipsychotics in schizophrenia. |
| Q34455825 | Double‐blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder |
| Q90634906 | Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia |
| Q43638445 | Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients |
| Q46029590 | Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. |
| Q46703910 | Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats. |
| Q44983975 | Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. |
| Q31023868 | Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: a comparison with clinical data |
| Q33738740 | Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study |
| Q35035145 | Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects |
| Q50609675 | Erectile dysfunction in a sample of patients attending a psychiatric outpatient department. |
| Q34708405 | Female sexual disorders: psychiatric aspects |
| Q35680852 | From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. |
| Q34392459 | Good tolerability equals good results: the patient's perspective |
| Q37663522 | Hormone profile in acute psychotic disorders: A cross-sectional comparison of serum hormone concentrations in treated and untreated male patients with schizophrenia |
| Q33195131 | Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone |
| Q46917137 | Long-acting neuroleptic use for reproductive management of non-domestic ungulates using the domestic goat (Capra hircus) as a model |
| Q34412065 | Neuroleptics in headache |
| Q35751533 | Osteoporosis screening and treatment in women with schizophrenia: a controlled study |
| Q36881409 | Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation |
| Q34544811 | Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers |
| Q37138734 | Prolactin levels in olanzapine treatment correlate with positive symptoms of schizophrenia: results from an open-label, flexible-dose study |
| Q39639409 | Prolactin, testosterone and cortisol as possible markers of changes in cardiovascular function associated with urbanization. |
| Q44264675 | Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol |
| Q36737420 | Regarding "A Risperidone-induced Prolactinoma Resolved When A Woman with Schizoaffective Disorder Switched to Ziprasidone: A Case Report". |
| Q57820223 | Relationship Between Plasma Levels of Prolactin and the Severity of Negative Symptoms in Patients with Schizophrenia |
| Q43608200 | Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol |
| Q38778145 | Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review |
| Q36836750 | Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia |
| Q37704057 | Sertraline Induced Galactorrhea |
| Q37456024 | The Effects of Antipsychotics on Prolactin Levels and Women's Menstruation. |
| Q46650329 | The effect of fluphenazine decanoate on glucocorticoid production, reproductive cyclicity, and the behavioral stress response in the Persian onager (Equus hemionus onager). |
| Q33619940 | The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. |
| Q35369968 | The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings |
| Q34708414 | The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women |
| Q35102481 | Understanding the new and evolving profile of adverse drug effects in schizophrenia |
| Q34869256 | Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability |
| Q31980098 | Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders |
| Q35089945 | What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? |
| Q34640811 | World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance |
| Q33223628 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia |
Search more.